Ernexa Therapeutics Net Profit Margin Growth & History (ERNA)
Ernexa Therapeutics's net profit margin was −7,652.75% for fiscal 2024.
View full Ernexa Therapeutics company overviewErnexa Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −7,652.75% | +24211.96 pp |
| 2023 | 2023-12-31 | −31,864.71% | — |
| 2020 | 2020-12-31 | −125.71% | −115.37 pp |
| 2019 | 2019-12-31 | −10.34% | −9.23 pp |
| 2018 | 2018-12-31 | −1.11% | +3.95 pp |
| 2017 | 2017-12-31 | −5.06% | +8.04 pp |
| 2016 | 2016-12-31 | −13.10% | +16.37 pp |
| 2015 | 2015-12-31 | −29.47% | −10.16 pp |
| 2014 | 2014-12-31 | −19.31% | −14.88 pp |
| 2013 | 2013-12-31 | −4.43% | −0.30 pp |
| 2012 | 2012-12-31 | −4.13% | +10.19 pp |
| 2011 | 2011-12-31 | −14.32% | −12.74 pp |
| 2010 | 2010-12-31 | −1.58% | — |
Ernexa Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −575,900.00% | — |
| Q3 2024 | 2024-09-30 | −5,462.83% | +5499.91 pp |
| Q2 2024 | 2024-06-30 | −11,763.83% | — |
| Q1 2024 | 2024-03-31 | −14,142.55% | — |
| Q3 2023 | 2023-09-30 | −10,962.75% | — |
| Q4 2020 | 2020-12-31 | −188.78% | −163.76 pp |
| Q3 2020 | 2020-09-30 | −136.77% | −129.11 pp |
| Q2 2020 | 2020-06-30 | −269.69% | −267.97 pp |
| Q1 2020 | 2020-03-31 | −42.57% | −36.10 pp |
| Q4 2019 | 2019-12-31 | −25.02% | −25.90 pp |
| Q3 2019 | 2019-09-30 | −7.66% | −11.36 pp |
| Q2 2019 | 2019-06-30 | −1.72% | +0.47 pp |
| Q1 2019 | 2019-03-31 | −6.48% | +0.62 pp |
| Q4 2018 | 2018-12-31 | 0.88% | +12.94 pp |
| Q3 2018 | 2018-09-30 | 3.70% | +7.24 pp |
| Q2 2018 | 2018-06-30 | −2.19% | +0.76 pp |
| Q1 2018 | 2018-03-31 | −7.10% | −5.38 pp |
| Q4 2017 | 2017-12-31 | −12.07% | −4.39 pp |
| Q3 2017 | 2017-09-30 | −3.54% | +6.99 pp |
| Q2 2017 | 2017-06-30 | −2.96% | +12.76 pp |
| Q1 2017 | 2017-03-31 | −1.72% | +17.27 pp |
| Q4 2016 | 2016-12-31 | −7.68% | +7.51 pp |
| Q3 2016 | 2016-09-30 | −10.53% | +11.65 pp |
| Q2 2016 | 2016-06-30 | −15.72% | +26.67 pp |
| Q1 2016 | 2016-03-31 | −18.99% | +20.53 pp |
| Q4 2015 | 2015-12-31 | −15.18% | +10.27 pp |
| Q3 2015 | 2015-09-30 | −22.17% | −0.28 pp |
| Q2 2015 | 2015-06-30 | −42.39% | −22.77 pp |
| Q1 2015 | 2015-03-31 | −39.52% | −29.41 pp |
| Q4 2014 | 2014-12-31 | −25.45% | −20.11 pp |
| Q3 2014 | 2014-09-30 | −21.90% | −17.66 pp |
| Q2 2014 | 2014-06-30 | −19.61% | −17.82 pp |
| Q1 2014 | 2014-03-31 | −10.11% | −4.08 pp |
| Q4 2013 | 2013-12-31 | −5.34% | −15.94 pp |
| Q3 2013 | 2013-09-30 | −4.23% | −5.13 pp |
| Q2 2013 | 2013-06-30 | −1.79% | +10521.90 pp |
| Q1 2013 | 2013-03-31 | −6.03% | +11.19 pp |
| Q4 2012 | 2012-12-31 | 10.60% | +27.62 pp |
| Q3 2012 | 2012-09-30 | 0.89% | +15.15 pp |
| Q2 2012 | 2012-06-30 | −10,523.69% | +5687.18 pp |
| Q1 2012 | 2012-03-31 | −17.23% | −7.91 pp |
| Q4 2011 | 2011-12-31 | −17.02% | — |
| Q3 2011 | 2011-09-30 | −14.25% | −16.16 pp |
| Q2 2011 | 2011-06-30 | −16,210.87% | −16203.49 pp |
| Q1 2011 | 2011-03-31 | −9.32% | — |
| Q3 2010 | 2010-09-30 | 1.91% | — |
| Q2 2010 | 2010-06-30 | −7.38% | — |
Ernexa Therapeutics net profit margin trends
Over the last five fiscal years, Ernexa Therapeutics's net profit margin decreased from −10.34% to −7,652.75%, a change of −7642.41 percentage points. The latest reported quarter, Q4 2024, shows −575,900.00%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ernexa Therapeutics source filings ↗